Research Projects

The Project eBrain-Health will deliver a distributed research platform for modeling and simulating complex neurobiological phenomena of human brain function and dysfunction in a data protection compliant environment. It will provide thousands of multilevel virtual brains from patients and healthy human controls for research and innovation. Brain...

The four-year MICRO-THERAPY is a fully integrated interdisciplinary proposal which will develop a new area of competence in the three partners, Liverpool John Moores University, University of Rennes1 and ManRos Therapeutics. It brings together a powerful set of partners covering fully the three key aspects - microwave engineering, chemistry and...

IMI’s growing neurodegenerative disorders (ND) portfolio is to get a new, dynamic platform – NEURONET – that will make it easier for the many projects to exploit synergies and connect the resources and needs of the different projects. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying...

ProtEprobe takes advantage of the recent cutting edge developments in protein conformation control at the Malliaras group and high sensitive protein sensing using high sensitivity factor triangular silver nanoplates by the fellow. Misfolding of a protein occurs when it becomes trapped in a local potential energy minimum where the conformation...

Therapies for neurological disorders often involve deeply invasive brain operations or implants. A largely overlooked aspect of these conditions is the high comorbidity of GI-related disorders. Although the top-down relationship between the brain and peripheral organs has dominated the field, its now clear that activity of peripheral organs, in...

Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease...

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information...

The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions.

To achieve this, EPAD...

Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent strength and time-to-market, which in turn will determine knowledge gain and availability of new treatments to patients. Recent publications report challenges with the robustness, rigor, and/or validity of...

'We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against...

Current theories of declarative memory suggest that it is supported by two complementary memory systems: the medial temporal lobe (MTL) which specializes in rapid acquisition of novel associations and the neocortex, which slowly learns through environmental regularities. Gilboa et al. recently reported an extraordinary phenomenon of rapid...

The general objective of the conference is to get a high level political commitment at the EU level to fight against the Alzheimer`s disease and related disorders which is a major public health threat.